Oral Answers to Questions

Crispin Blunt Excerpts

Wednesday 21st February 2018 Commons Chamber

[The Prime Minister]

The hon. Gentleman raises an important point. As he may know, there are two ways in which those rehabilitation services will be commissioned. NHS England commissions specialised neurological rehabilitation centres for complex brain injury, and it does so at a national level. More routine rehabilitation is commissioned locally, although NHS England sets guidelines for commissioners to support delivery, including for brain injury. The hon. Gentleman raises an important point, and I will ask the Health Secretary to respond to him and the specific question that he asks.

[Crispin Blunt (Reigate) (Con)]

May I tell the Prime Minister how welcome the Policing Minister’s response to yesterday’s urgent question was, as he said that he would help Alfie Dingley to find a way through regulations to access the medicinal cannabis that he needs? Will the Prime Minister ensure not only that the Minister’s words go beyond the popular view of, “I’m from the Government; I’m here to help,” but that we join the majority of states of the European Union and the United States, as well as British public opinion and all colleagues who raised questions yesterday, so that we give British citizens the earliest possible access to the potential benefits of medicines derived from cannabis through a proper evidence-based process? Will she ensure that the United Kingdom is on the front foot in licensing all medical investigations that need to be done to get us these benefits?

[The Prime Minister]

I know that the sympathies of Members across the House are with Alfie and his family as he undergoes treatment. We recognise that people with chronic pain and debilitating illnesses will always look to alleviate their symptoms, but if we are going to permit medicines to be used, we first need to ensure that they have been through the most rigorous testing and that we apply the most rigorous standards. We believe that cannabis should be subjected to the same regulations that apply to all medicines in the United Kingdom.